IMPRiND partner CNRS research shows diagnostic & therapeutic potential in the prion-like propagation of fibrillar aSYN, as they can facilitate the design of ligands that specifically bind & distinguish between fibrillar polymorphs. Read the publication.
IMI is organising a series of online live sessions on IMI’s Impact, where key actors will explore the challenges and demonstrate how IMI contributed. As part of this event a IMI impact on dementia Event will be organised on 15 June 2021, 2:00 - 4:00 CEST.
The event comprises of a series of presentations including a talk on NEURONET by our Project Coordinator Carlos Diaz. To learn more about the event
IMPRiND partners Tofaris (UOXF), Melki (CNRS), Bose (Lilly) and McEwan (LMB) will present at the International Festival of Neuroscience during the Symposium Protein aggregation in Parkinson's and Alzheimer's disease: from mechanisms to targets for therapies on Wednesday 14 April.
Today Erwan Bezard from the UBx team was interviewed on the topic of "The search for better animal models of
Alzheimer’s disease" by the leading online community for Alzheimer's & dementia patients & caregivers: Being Patient.
This interview will be featured in the next couple of weeks as part of their "Talk with experts" series.
This project receives funding from the Innovative Medicines Initiative 2 Joint Undertaking (www.imi.europa.eu) under grant agreement No 116060. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
This work is supported by the Swiss State Secretariat for Education‚ Research and Innovation (SERI) under contract number 17.00038.
The opinions expressed and arguments employed herein do not necessarily reflect the official views of these funding bodies.